Abstract

Heat shock proteins (HSPs) were discovered in the early 1960s as important intracellular proteinaceous components that aid in stress physiology and reprogram cellular responses to allow the organism to survive. HSPs were discovered in extracellular spaces in the early 1990s and were shown to activate gamma-delta T-lymphocytes. Subsequent research linked them to a variety of diseases, including autoimmune disorders, diabetes, cancer, hepatic, pancreatic, and renal illnesses, and cachexia. In recent years, there has been a lot of excitement and enthusiasm surrounding the idea of HSP-targeted new molecular therapies.